Tags

Type your tag names separated by a space and hit enter

Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Saudi J Kidney Dis Transpl. 2010 Nov; 21(6):1021-9.SJ

Abstract

Individuals with chronic renal disease (CKD) are prone to have accelerated process of atherosclerosis. Importantly, cardiovascular disease is the main cause of morbidity and mortality in kidney transplant recipients. Recent studies suggest a potential benefit of the lipid lowering medica-tions in preventing cardiovascular events in the CKD and the transplant populations. In particular, statin was shown to be effective in reducing low density lipoprotein (LDL)-cholesterol. However, refractory dyslipidemia and difficulty in lowering LDL to target were reported with the CKD and the kidney transplant patients. The second United Kingdom Heart and Renal protection study (UK-HARP-II) showed that the addition of ezetimibe to simvastatin was safe and effective in treating dyslipidemia in CKD. Furthermore, the combination of ezetimibe and statin was also effective and safe in treating dyslipidemia in kidney transplant recipients. The Study of Heart and Renal Pro-tection (SHARP) trial will evaluate the effects of lowering LDL-C with ezetimibe 10 mg and simvastatin 20 mg daily versus placebo in 9,000 patients with chronic kidney disease. The current evidence suggests that the addition of ezetimibe to satin is effective and safe in treating dyslipidemia in the CKD and the kidney transplant patients. Future clinical trials are needed to determine whether ezetimibe will reduce cardiovascular risk in the CKD patients.

Authors+Show Affiliations

Ahmed MH
Division of Acute Medicine, The James Cook University Hospital, Marton Road, Middlesbrough, United Kingdom. elziber@yahoo.com
Khalil AA
No affiliation info available

MeSH

Anticholesteremic AgentsAzetidinesBiomarkersCardiovascular DiseasesCholesterol, LDLDown-RegulationDrug Therapy, CombinationDyslipidemiasEvidence-Based MedicineEzetimibeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKidney Failure, ChronicKidney TransplantationTreatment Outcome

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21060168

Citation

Ahmed, Mohamed H., and Atif A. Khalil. "Ezetimibe as a Potential Treatment for Dyslipidemia Associated With Chronic Renal Failure and Renal Transplant." Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, vol. 21, no. 6, 2010, pp. 1021-9.
Ahmed MH, Khalil AA. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi J Kidney Dis Transpl. 2010;21(6):1021-9.
Ahmed, M. H., & Khalil, A. A. (2010). Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 21(6), 1021-9.
Ahmed MH, Khalil AA. Ezetimibe as a Potential Treatment for Dyslipidemia Associated With Chronic Renal Failure and Renal Transplant. Saudi J Kidney Dis Transpl. 2010;21(6):1021-9. PubMed PMID: 21060168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. AU - Ahmed,Mohamed H, AU - Khalil,Atif A, PY - 2010/11/10/entrez PY - 2010/11/10/pubmed PY - 2011/2/17/medline SP - 1021 EP - 9 JF - Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia JO - Saudi J Kidney Dis Transpl VL - 21 IS - 6 N2 - Individuals with chronic renal disease (CKD) are prone to have accelerated process of atherosclerosis. Importantly, cardiovascular disease is the main cause of morbidity and mortality in kidney transplant recipients. Recent studies suggest a potential benefit of the lipid lowering medica-tions in preventing cardiovascular events in the CKD and the transplant populations. In particular, statin was shown to be effective in reducing low density lipoprotein (LDL)-cholesterol. However, refractory dyslipidemia and difficulty in lowering LDL to target were reported with the CKD and the kidney transplant patients. The second United Kingdom Heart and Renal protection study (UK-HARP-II) showed that the addition of ezetimibe to simvastatin was safe and effective in treating dyslipidemia in CKD. Furthermore, the combination of ezetimibe and statin was also effective and safe in treating dyslipidemia in kidney transplant recipients. The Study of Heart and Renal Pro-tection (SHARP) trial will evaluate the effects of lowering LDL-C with ezetimibe 10 mg and simvastatin 20 mg daily versus placebo in 9,000 patients with chronic kidney disease. The current evidence suggests that the addition of ezetimibe to satin is effective and safe in treating dyslipidemia in the CKD and the kidney transplant patients. Future clinical trials are needed to determine whether ezetimibe will reduce cardiovascular risk in the CKD patients. SN - 1319-2442 UR - https://www.unboundmedicine.com/medline/citation/21060168/Ezetimibe_as_a_potential_treatment_for_dyslipidemia_associated_with_chronic_renal_failure_and_renal_transplant_ DB - PRIME DP - Unbound Medicine ER -